分子靶向药物治疗肝细胞癌的临床应用进展

Clinical application of molecular targeted agents in hepatocellular carcinoma

肝细胞癌（肝癌）是最常见的恶性肿瘤，因其发病隐匿、发展迅速等特征，多数肝癌患者确诊时已属中晚期而失去根治的机会。近年来，靶向药物成为治疗中晚期肝癌的重要方法之一。索拉非尼是目前唯一被批准用于一线治疗晚期肝细胞癌的靶向药物。研究表明，索拉非尼虽然可使部分中晚期肝癌患者获益，但是其耐药问题也逐渐受到重视。目前已有较多针对肝癌的新型靶向药物不断研发和推出，然而仅有少数药物的疗效获得被肯定。本文主要介绍了目前肝癌分子靶向治疗的研究进展。

Hepatocellular carcinoma （HCC） is the most common malignant tumor. Many patients with HCC lose the operation chances and have bad outcomes. In recent years, molecular targeted therapies have received signifi- cant attention in the treatment of HCC. Sorafenib was the only targeted agent that approved for the first - line treating advanced HCC. Although many studies have showed clinical benefit in some HCC patients received Sorafenib, drug re- sistance is becoming more and more protrusive. Newly developed drugs for advanced HCC are investigated continually, but only a few drugs achieve satisfactory therapeutic effects. This paper aims to introduce the research status of molecu- lar targeted therapies in advanced HCC.